

Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting – October 13, 2010 @ 6:00 p.m.

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

- 1. Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. Muchmore, Chairman:

- 2. Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

- 3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. September 8, 2010 DUR Minutes – Vote
 - B. September 9, 2010 DUR Recommendation Memorandum
 - C. Correspondence

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

- 4. Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Retrospective Drug Utilization Review for August 2010
 - B. Medication Coverage Activity Audit for September 2010
 - C. Help Desk Activity Audit for September 2010

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

- 5. Action Item – Annual Review of Growth Hormones - See Appendix C.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

- 6. Action Item – Annual Review of Erythropoietin Stimulating Agents - See Appendix D.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

7. **Action Item – Annual Review of Narcotics and 30 Day Notice to Prior Authorize Butrans™, Primlev™, Xolox®, Exalgo™ ER, Rybix™ ODT, and Suboxone® / Subutex® – See Appendix E.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - B. COP Recommendations

Items to be presented by Dr. Patel, Dr. Muchmore, Chairman

8. **Action Item – Annual Review of NSAIDs and 30 Day Notice to Prior Authorize Vimovo™ – See Appendix F.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Robinson, Dr. Muchmore, Chairman

9. **Action Item – Annual Review of Ocular Allergy Medications and 30 Day Notice to Prior Authorize Bepreve™ and Lastacaft™ – See Appendix G.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

10. **FDA and DEA Updates – See Appendix H.**
11. **Future Business**
 - A. Utilization Review of Alzheimer's Medications
 - B. Utilization Review of BPH Medications
 - C. Annual Review Antihypertensives
 - D. New Product Reviews
12. **Adjournment**